Patents Examined by Satyanarayana R. Gudibande
  • Diamide inhibitors of cytochrome P450
    Patent number: 9540354
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: January 10, 2017
    Assignee: SEQUOIA PHARMACEUTICALS, INC.
    Inventors: Michael Eissenstat, Dehui Duan
  • Compositions comprising a SIRT6 activator and a DNA repair enzyme
    Patent number: 9539196
    Abstract: Compositions of the invention comprise 8-oxoguanine glycosylase (OGG1) and SIRT6 activating peptide G-A-G-V-S-A-E-NH2. Compositions of the invention exhibit anti-aging effects by promoting the repair of skin cell DNA and/or by protecting skin cell DNA from UV damage.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: January 10, 2017
    Assignee: ELC MANAGEMENT, LLC
    Inventors: Nadine Pernodet, Kelly Dong, Edward Pelle
  • Therapeutic agent for pulmonary emphysema
    Patent number: 9533070
    Abstract: The invention has as its object the provision of a medicine capable of reducing a volume of emphysema-suffering pulmonary alveoli or alveolar sacs by means of a respiratory region volume inhibitor containing a coating film formation as a main component and capable of forming a coating film in a respiratory region, characterized by being used in such a way that the coating film-forming component is administered to an emphysema-suffering pulmonary alveolar parenchyma in a human-respiratory region in an amount of 0.004 to 200 g/application, preferably 0.07 to 20 g/application and more preferably 0.5 to 5 g/application on each occasion.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: January 3, 2017
    Assignee: Terumo Kabushiki Kaisha
    Inventors: Takao Anzai, Atsuhiko Nogawa, Yuichi Tada
  • Stabilized p53 peptides and uses thereof
    Patent number: 9527896
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: December 27, 2016
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Stanley J. Korsmeyer
  • Fusion proteins of collagen-binding domain and parathyroid hormone
    Patent number: 9528099
    Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: December 27, 2016
    Assignees: National University Corporation Kagawa University
    Inventors: Robert C. Gensure, Joshua Sakon, Osamu Matsushita, Tulasi Ponnapakkam
  • Delivery of therapeutic agents by a collagen binding protein
    Patent number: 9526765
    Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: December 27, 2016
    Assignees: The Kitasato Institute
    Inventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
  • Aligned nanofibers and related methods of use
    Patent number: 9512404
    Abstract: The present invention relates to nanofibers. In particular, the present invention provides aligned nanofiber bundle assemblies. In some embodiments, the aligned nanofiber bundle assemblies are used for tissue regeneration, controlled growth of cells, and related methods (e.g., diagnostic methods, research methods, drug screening).
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: December 6, 2016
    Assignee: Northwestern University
    Inventors: Samuel I. Stupp, Shuming Zhang, Alvaro Mata, Megan A. Greenfield
  • Compositions and methods for cancer treatment using targeted carbon nanotubes
    Patent number: 9504745
    Abstract: Compositions for detecting and/or destroying cancer tumors and/or cancer cells via photodynamic therapy are disclosed, as well as methods of use thereof. The compositions comprise a linking protein or peptide attached to or otherwise physically associated with a carbon nanotube to form a targeted protein-carbon nanotube complex.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: November 29, 2016
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Roger G. Harrison, Jr., Daniel E. Resasco, Luis Filipe Ferreira Neves
  • Method for identifying novel minor histocompatibility antigens
    Patent number: 9500651
    Abstract: A novel method for human minor histocompatibility antigen (MiHA) discovery, novel MiHAs identified using this method, as well as uses of the novel MiHAs, are described. One of the features of the novel method is the inclusion of personalized translated transcriptome and/or exome in the database used for peptide identification by mass spectroscopy (MS). Candidate MiHAs are identified by comparing the personalized transcriptome and/or exome to a reference genome and/or to the transcriptome and/or exome of an HLA-matched subject.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: November 22, 2016
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Claude Perreault, Pierre Thibault, Sébastien Lemieux, Diana Paola Granados, Sriranganadane Dev, Mohamed Tariq Daouda, Olivier Caron-Lizotte
  • Neprilysin inhibitors
    Patent number: 9499487
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, X, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: November 22, 2016
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
  • Gamma-AApeptides with potent and broad-spectrum antimicrobial activity
    Patent number: 9499587
    Abstract: The present invention is directed to a novel class of antimicrobial agents called ?-AApeptides. The current invention provides various categories of ?-AApeptides, for example, linear ?-AApeptides, cyclic ?-AApeptides, and lipidated ?-AApeptides. ?-AApeptides of the current invention are designed to exert antimicrobial activity while being stable and non-toxic. ?-AApeptides also do not appear to lead to the development of microbial resistance in treated microorganisms. Thus, the disclosed ?-AApeptides can be used for the treatment of various medical conditions associated with pathogenic microorganisms.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: November 22, 2016
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jianfeng Cai, Youhong Niu, Haifan Wu, Shruti Padhee
  • Composition and methods for stimulating gastrointestinal motility
    Patent number: 9499599
    Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: November 22, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Rakesh Datta, Zheng Xin Dong
  • Modulation of synaptic maintenance
    Patent number: 9493555
    Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: November 15, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ben A. Barres, Beth A. Stevens
  • Extracting hirudin from leech in vivo
    Patent number: 9481718
    Abstract: Described herein relates to methods and compositions for extracting hirudin from a plurality of leeches in vivo. The method may include contacting leeches with inducing membranes containing an inducing agent for a first predetermined time period. The inducing membranes may be removed from the leeches, and the leeches may be contacted with a regurgitation agent for a second predetermined time period in a container such that the leeches are induced to regurgitate regurgitation contents. The regurgitation contents may be collected and purified to obtain the hirudin.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: November 1, 2016
    Assignee: North American Hirudin Supplement Products Inc.
    Inventor: Weiguan Zhou
  • Modulation of synaptic maintenance
    Patent number: 9480658
    Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: November 1, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ben A. Barres, Alexander H. Stephan, Beth A. Stevens
  • Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
    Patent number: 9474792
    Abstract: Methods of treating or ameliorating metabolic diseases using a PLA2G12A polypeptide or PLA2G12A mutant polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes mellitus, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 25, 2016
    Assignee: Amgen Inc.
    Inventors: Daniel C. H. Lin, Jinghong Wang, Yang Li
  • Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
    Patent number: 9475839
    Abstract: A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: October 25, 2016
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Nadya I. Tarasova, Giorgio Trinchieri, Howard A. Young, C. Andrew Stewart, Marco A. Cardone, Alan O. Perantoni
  • Romidepsin formulations and uses thereof
    Patent number: 9468664
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 18, 2016
    Assignee: Celgene Corporation
    Inventors: Lianfeng Huang, Ho-Wah Hui, Vijay Naringrekar, Gang Yang
  • Neurturin molecules
    Patent number: 9469679
    Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: October 18, 2016
    Assignee: NTF Therapeutics, Inc.
    Inventors: Pia Runeberg-Roos, Maxim M. Bespalov, Richard Penn, Mart Saarma
  • Romidepsin formulations and uses thereof
    Patent number: 9463215
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 11, 2016
    Assignee: Celgene Corporation
    Inventors: Lianfeng Huang, Ho-Wah Hui, Vijay Naringrekar, Gang Yang